View Item 
      •   UMY Repository
      • 03. DISSERTATIONS AND THESIS
      • Students
      • Undergraduate Thesis
      • Faculty of Medicine and Health Science
      • Department of Medical Education
      • View Item
      •   UMY Repository
      • 03. DISSERTATIONS AND THESIS
      • Students
      • Undergraduate Thesis
      • Faculty of Medicine and Health Science
      • Department of Medical Education
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      ANALISIS EFEKTIVITAS BIAYA TERAPI KOMBINASI DARI RISPERIDON DAN HALOPERIDOL PADA FASE AKUT PASIEN SKIZOFRENIA

      Thumbnail
      View/Open
      COVER (8.172Kb)
      HALAMAN JUDUL (275.8Kb)
      HALAMAN PENGESAHAN (180.3Kb)
      ABSTRACT (89.23Kb)
      BAB I (310.8Kb)
      BAB II (279.0Kb)
      BAB III (182.0Kb)
      BAB IV (287.9Kb)
      BAB V (84.03Kb)
      DAFTAR PUSTAKA (221.2Kb)
      LAMPIRAN (1.523Mb)
      NASKAH PUBLIKASI (374Kb)
      Date
      2016-03-14
      Author
      KINANTI, SEKAR
      Metadata
      Show full item record
      Abstract
      Schizophrenia is a severe mental disorder characterized by a decrease or an inability to communicate, impaired reality, affective unnatural, cognitive impairment and difficulty performing daily activities. Schizophrenia consists of three phases, that are acute phase, the stabilization phase and stable phase. Therapeutic target based on the phase and severity of illness. In the acute phase, the goal is reduce or eliminate the psychotic symptoms and improve the patient's normal function. Treatment at this phase lasts for the first 7 days. Pharmacologic therapy is used in the form of antipsychotic drugs which divided into two groups, typical antipsychotics and atypical antipsychotics. Many schizophrenic patients relapse due to economic factors. Overall cost in one episode of schizophrenia spend an average total cost of Rp 1.817.466,00. Objective : Analyze the cost-effectiveness of combination therapy between Risperidone and Haloperidol on the acute phase of schizophrenia patients. Methods : The study was non-experimental descriptive method through a retrospective analysis. The total sample is 40 people. Cost-effectiveness analysis is done using cost-effectiveness diagram. Result : The average cost of Risperidone combination therapy is Rp 31.191,40 ± Rp 8.545,114 with minimal cost Rp 7.598,00 and maximum cost Rp 139.560,00; and the average cost of Haloperdiol combination therapy is Rp 11.186,95 ± Rp 1.163,970 with minimal cost Rp 3.223,00 and maximum cost Rp 18.995,00. Based on the Mann-Whitney test, p <0.05 so there is significant difference between the cost of Risperidone combination therapy and Haloperidol combination therapy. Conclusion : The results of cost-effectiveness analysis is Haloperidol combination therapy better than Risperidone combination therapy on the acute phase of schizophrenia patients.
      URI
      http://repository.umy.ac.id/handle/123456789/5851
      Collections
      • Department of Medical Education

      DSpace software copyright © 2002-2015  DuraSpace
      Contact Us | Send Feedback
      Theme by 
      @mire NV
       

       

      Browse

      All of UMY RepositoryCollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

      My Account

      Login

      DSpace software copyright © 2002-2015  DuraSpace
      Contact Us | Send Feedback
      Theme by 
      @mire NV